Alchemix: a novel alkylating anthraquinone with potent activity against anthracycline- and cisplatin-resistant ovarian cancer.
Paniwnyk, Z. Teesdale-Spittle, P.H. Plumb, J.A. Willmore, E. Austin, C.A. Patterson, Laurence H.
Paniwnyk, Z.
Teesdale-Spittle, P.H.
Plumb, J.A.
Willmore, E.
Austin, C.A.
Patterson, Laurence H.
Publication Date
2003
End of Embargo
Supervisor
Rights
Peer-Reviewed
Yes
Open Access status
closedAccess
Accepted for publication
Institution
Department
Awarded
Embargo end date
Collections
Additional title
Abstract
Chloroethylaminoanthraquinones are described with intercalating and alkylating capacity that potentially covalently cross-link topoisomerase II (topo II) to DNA. These compounds have potent cytotoxic activity (IC(50) = 0.9-7.6 nM) against the A2780 human ovarian carcinoma cell line. Hydroxyethylaminoanthraquinones also reported in this paper have similar IC(50) values (0.7-1.7 nM) in the same cell line. Alchemix (ZP281M, 1-(2-[N,N-bis(2-chloroethyl)amino]ethylamino)-4-(2-[N,N-(dimethyl)amino]ethylamino)-5,8-dihydroxy-9,10-anthracenedione), an alkylating anthraquinone, retains excellent antitumor activity in Adriamycin-resistant (2780AD) and cisplatin-resistant (2780/cp70) cell lines in vitro and in vivo. This indicates that Alchemix can evade both P-glycoprotein efflux pump and DNA mismatch repair-mediated resistance. In treated cells, Alchemix was shown to preferentially induce drug-stabilized covalent bound topo IIalpha-DNA complexes over topo IIbeta-DNA complexes.
Version
No full-text in the repository
Citation
Pors, K., Paniwnyk, Z., Teesdale-Spittle, P., Plumb, J.A. and Patterson, L.H. (2003). Alchemix: a novel alkylating anthraquinone with potent activity against anthracycline- and cisplatin-resistant ovarian cancer. Molecular Cancer Therapeutics. Vol 2, No. 7, pp. 607-610.
Link to publisher’s version
Link to published version
Link to Version of Record
Type
Article